Tenosynovitis occurs in a subset of patients with RA, even in patients with no metacarpophalangeal joint synovitis (90), and these patients could benefit from an anti-IL-17A therapeutic approach if they do not fully respond to the specific biologic agent (83). Here, IL17A is linked to rheumatoid arthritis.